Full-Time

Key Account Manager

Posted on 10/31/2025

Nomic

Nomic

51-200 employees

high-throughput proteomics platform employing nELISA

No salary listed

San Francisco, CA, USA

In Person

Hybrid role; on-site in San Francisco Bay Area; travel ~50%.

Category
Sales & Account Management (1)
Required Skills
Sales
Requirements
  • Experience: 5+ years in technical or strategic sales within Pharma/Biotech, with a proven track record of meeting or exceeding targets.
  • Background: Strong scientific foundation (MS or PhD in Molecular Biology, Biochemistry, Immunology, or related field preferred).
  • Commercial Skills: Enterprise-level selling experience with Big Pharma, ideally within proteomics, biomarkers, or drug discovery technology.
  • Technical Fluency: Ability to credibly discuss proteomic use cases in drug discovery, translational biomarkers, and clinical development.
  • Travel: Willingness to travel ~50% as needed.
Responsibilities
  • Own and expand relationships with top pharmaceutical accounts, developing and executing account-specific strategies.
  • Prospect and engage new customers within the biopharma space, generating net-new business.
  • Lead high-level conversations with senior executives while also delivering technical presentations to scientific teams.
  • Manage complex sales cycles, balancing strategic enterprise penetration with shorter transactional opportunities.
  • Provide scientific and commercial insights that influence customer decision-making and adoption of proteomic technologies.
  • Partner closely with internal Field Application Scientists, Technical Sales Managers, and Product teams to deliver impactful solutions.
  • Represent Nomic at key industry and academic conferences as both a business and technical commercial lead.
  • Maintain accurate pipeline visibility and forecasting through CRM and funnel management.
Desired Qualifications
  • Established relationships across Translational Biomarkers, Target Discovery, and Clinical Biomarkers functions strongly preferred.
  • Experience within proteomics, biomarkers, or drug discovery technology is desirable.
  • MS or PhD in Molecular Biology, Biochemistry, Immunology, or related field preferred.

Nplex Biosciences develops proteomics tools using nanotechnology, including the nELISA platform for high-throughput protein measurement. The platform uses DNA nanotechnology to identify proteins on micron-sized beads, enabling miniaturized, highly parallel immunoassays. It differentiates itself by combining DNA-based protein identification with bead-based assays and a scalable, cost-efficient workflow that lowers the cost of antibody-based proteomics. Its goal is to provide a reliable, scalable proteomics platform that supports drug discovery, biomarker discovery, and personalized medicine.

Company Size

51-200

Company Stage

Series B

Total Funding

$60.1M

Headquarters

Montreal, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Omni 1000 democratizes proteome-wide profiling for drug discovery and biomarker validation.[5]
  • $42M Series B September 2024 funds commercial expansion amid rising demand.[5]
  • Context-specific ~300-protein panels enable targeted discovery without multiplexing limitations.[2]

What critics are saying

  • Olink's Explore HT delivers 6000+ proteins, capturing larger pharma budgets.[1]
  • SomaScan's 11,000-protein aptamer technology erodes biomarker discovery market share.[1]
  • Post-Series B cash burn exceeds revenue as manufacturing scales in 2026.[1]

What makes Nomic unique

  • nELISA technology enables 1000-plex protein measurement at $50 per sample affordably.[5]
  • DNA-barcoded beads decode protein identity on standard flow cytometers seamlessly.[3]
  • End-to-end service model compatible with existing lab workflows and automation.[4]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

4%

2 year growth

1%
Yahoo Finance
Sep 19th, 2024
Nomic® Secures $42M in Oversubscribed Series B to Expand Access to Protein Profiling

MONTREAL, September 17, 2024--Nomic Bio ("Nomic"), the Protein Profiling company, today announces the completion of an oversubscribed $42 million Series B funding round. The fresh capital will enable Nomic to accelerate the expansion of its commercial operations, further invest in advancing its state-of-the-art protein profiling platform, and broaden its transformative offerings to meet growing demand.

BetaKit
Mar 18th, 2020
11 Canadian companies in Y Combinator’s Winter 2020 Demo Day

This week, Y Combinator (YC) held its Winter 2020 Demo Day, the 30th for the Silicon Valley incubator. To minimize health concerns during the COVID-19 outbreak, YC opted to host the demo day online. For this cohort, 16 Canadian startups participated.

TechCrunch
Mar 17th, 2020
All the companies from Y Combinator’s W20 Demo Day, Part IV: Healthcare, Biotech, Fintech and Nonprofits

Y Combinator’s Demo Day was a bit different this time around.

INACTIVE